SCHEMBL650733

SCHEMBL650733

CCOc1cccc(CN(Cc2ccc3c(c2)OCCO3)Cc2c(Cl)nc(-c3ccccc3C)n2C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
MAPK1 P28482 1/20 0.36
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MAOA P21397 2/20 0.35
MAOB P27338 2/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
PIK3CD O00329 1/20 0.35
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GAA P10253 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
SQLE Q14534 1/20 0.34
METAP2 P50579 1/20 0.34
F2R P25116 1/20 0.34
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648590 0.91 C5AR1 (0.40) ALDH1A1MAPK1OPRM1OPRD1MEN1
SCHEMBL1913077 0.86 CXCR3 (0.33) ALDH1A1MAPK1OPRM1OPRD1MEN1
SCHEMBL649494 0.84 C5AR1 (0.44) ALDH1A1MAPK1OPRM1OPRD1MEN1
SCHEMBL5136781 0.82 HTR2C (0.38) MEN1KMT2ASMN1; SMN2PTGDR2METAP2
SCHEMBL648633 0.82 C5AR1 (0.50) ALDH1A1MAPK1OPRM1OPRD1MEN1
SCHEMBL650187 0.82 SLC6A2 (0.35) MAPK1SQLE
SCHEMBL652511 0.82 C5AR1 (0.39) ALDH1A1MAPK1OPRM1OPRD1MEN1
SCHEMBL650106 0.81 C5AR1 (0.40) ALDH1A1MAPK1OPRM1OPRD1MEN1
SCHEMBL648144 0.81 C5AR1 (0.49) ALDH1A1MAPK1OPRM1OPRD1MEN1
SCHEMBL1913078 0.81 C5AR1 (0.45) ALDH1A1MAPK1OPRM1OPRD1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed